SPY316.27-0.78 -0.25%
DIA260.87-2.13 -0.81%
IXIC10,456.82+23.17 0.22%

Merck's KEYTRUDA Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1

Benzinga · -